TapImmune Inc (TPIV.OQ)
14 Dec 2017
Get access to over 18 million research reports from over 1,700 sources.
For several years, Reuters.com has provided analyst research reports for downloading. In an effort to streamline our website, analyst research will now be available from our dedicated page for Thomson Reuters On Demand, and the Reuters service will discontinue as of September 30, 2016.
Thomson Reuters On Demand provides over 18 million research reports from 1,700 sources.
Moreover, Thomson Reuters On Demand offers fast and cost-effective solutions that would allow you to retrieve information on:
- private equity
- third-party document and information retrieval
- and much, much more…
Click here to request a report and the team of expert analysts will get back to you shortly, to ensure you get the report you need.
|44||2017||President, Chief Executive Officer, Director|
|48||2016||Chief Financial Officer, Chief Accounting Officer, Treasurer, Corporate Secretary|
|60||2014||Vice President Development|
|57||2017||Acting Chief Medical Officer|
- BRIEF-Tapimmune Q3 loss earnings per share $0.39
- BRIEF-TapImmune appoints Peter Hoang as president and CEO
- BRIEF-Tapimmune files for resale of 4.4 mln shares of common stock held by selling stockholders
- BRIEF-TapImmune reaches 50 pct patient enrollment benchmark in phase 2 study of novel t-cell vaccine targeting triple-negative breast cancer
- BRIEF-TapImmune to raise $6.82 million in a private placement